Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573937 | 1.00 | CCR2 (0.58) | CCR2MEN1KMT2AGPR183GAA | |
| Hydrochloric Acid SCHEMBL5573104 | 0.99 | CCR2 (0.57) | CCR2MEN1KMT2AGPR183GAA | |
| Hydrochloric Acid SCHEMBL5573109 | 0.99 | CCR2 (0.57) | CCR2MEN1KMT2AGPR183GAA | |
| SCHEMBL7679652 | 0.82 | GAA (0.62) | MEN1KMT2AGPR183GAANPC1 | |
| SCHEMBL29738483 | 0.79 | ALOX5 (0.66) | MEN1KMT2AGPR183GAANPC1 | |
| SCHEMBL3767721 | 0.71 | MEN1 (0.56) | CCR2MEN1KMT2AGPR183GAA | |
| SCHEMBL3767727 | 0.71 | MEN1 (0.56) | CCR2MEN1KMT2AGPR183GAA | |
| SCHEMBL30716143 | 0.71 | GAA (0.67) | CCR2MEN1KMT2AGPR183GAA | |
| SCHEMBL27093043 | 0.71 | GAA (0.67) | CCR2MEN1KMT2AGPR183GAA | |
| SCHEMBL18840986 | 0.71 | CCR2 (1.00) | CCR2GPR183NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | CCR2 752/4885MEN1 2904/4885KMT2A 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.